bluuebunny/crossref_metadata_2025 huggingface dataset:
Low voltage area in the left atrial anterior wall predict Marshall-PLAN failure in patients with persistent atrial fibrillation
Authors: Limite L , Lagrange P , Bortone A , Khoueiry Z
Published: May 2024

Background

The most appropriate ablation strategy for persistent atrial fibrillation (PeAF) has not yet been determined. However, ethanol infusion of the vein of Marshall (VOM) combined with a linear set of ablation lesions (namely the Marshall-PLAN) has yielded encouraging results (1).

Purpose

Our study aimed at analyzing the relationship between low voltage areas (LVA) and arrhythmias recurrences in a PsAF population treated with the Marshall-PLAN.

Methods

we conducted a retrospective study on consecutive patients undergoing first catheter ablation (CA) for PsAF between 2021 and 2022 at our center. Pulmonary vein isolation (PVI), mitral isthmus ablation (VOM ethanol infusion, endocardial ablation and epicardial ablation in the great cardiac vein), left atrial (LA) roofline and cavo-tricuspid isthmus ablation were carried out in all the patients. Bidirectional block was validated for all the linear lesions as well as for PVI. Pre-ablation LA electroanatomic maps were built with CARTOv3 system and the PentaRay mapping catheter (minimum 3000 points). LVA were identified as areas >1cm2 (containing ≥3 neighboring points with ≤10mm distance) with bipolar voltage <0.5mV in SR and <0.24 mV in AF (2). All patients were followed for at least 12 months.

Results

Overall, 93 patients (69±7years, 30% female) with PsAF were included. Their left-ventricle ejection fraction and left atrial volume indexed for body surface area (LAVI) were 57% and 92±20 ml/m2. LA maps demonstrated at least one LVA in 70 subjects (75.3%). The mean relative surface of LA in which a LVA was evidenced was 8±14%. LVA were found within the anterior LA wall in 49 patients (53%), in the posterior wall in 33 patients (35.5%), in the inferior wall in 22 patients (24%), in the lateral wall in 14 patients (15.1%) and in the pulmonary vein region in 44 patients (47.3%). After 19±6 months of follow-up, 28 (30%) patients had AF recurrence. At Cox regression analysis (including LVA burden and LAVI dimensions), LVA localized within the anterior LA wall were predictive of arrhythmia recurrences (hazard ratio [HR] 2.0 [95% CI, 1.1–4.7], P=0.04). Kaplan-Meier estimates of survival free from recurrences at 20 months were 51% and 88% in patients with and without LVAs in the anterior LA wall (Log-rank 0.006).

Conclusions

The Marshall-PLAN led to a global AF-free survival of 70% after 19±6 months in our cohort of patients with PsAF. Importantly however, the data show that the subset of patients with LVA in the anterior LA wall (i.e., the LA region not targeted by the pre-specified ablation set here evaluated) have a 55%-only AF-free survival while that of patients without LVA in the anterior LA wall was of 88%. As a result, our study supports the relevance of atrial substrate assessment and the possibility of CA strategy optimization in the subset of patients with PsAF and LVA in the anterior LA wall (3).
How to easily detect residual conduction gaps in redo procedure of pulmonary vein isolation: Post Encircling Mapping (PEM)
Authors: La Greca C , Prezioso A , Zanchi S , Pecora D
Published: May 2024

Background

Pulmonary vein isolation (PVI) is the cornerstone of the interventional catheter-based treatment of atrial fibrillation. Unfortunately, persistent pulmonary vein isolation is difficult to achieve, and up to 70% of pulmonary vein reconnection rate has been documented (1). Atrial mapping during pacing from CS in combination with LAT (local activation time) mapping may help to identify these residual gaps (2).

Methods

We collected data from consecutive radiofrequency (RF) redo PVI procedures performed in our center from 01/01/2022 to 01/10/2023. Re-isolation was obtained based on bipolar map and Local Activation Time (LAT) map during pacing from distal coronary sinus (CS) -table 1 for the workflow-. We compared data obtained from analysis of bipolar maps and LAT maps; "discrepancy" between bipolar map and LAT map was defined as a difference which may lead to a different approach to the ablation strategy (figure 1); then, we compared procedural timing (radiofrequency time, fluoroscopy time, and skin-to-skin time) with our historical cohort of RF redo PVI procedures (01/01/2011 – 31/12/2021).

Results

We performed 34 radiofrequency redo procedure from 01/01/2022 to 01/10/2023. In 13 out of 112 veins treated (11.6%), we observed discrepancy between bipolar map and LAT map. We observed a lower radiofrequency time for patients treated on the basis of LAT map (01-01-2022 – 01-10-2022) when compared with our historical cohort (1023.21 ± 521.51 sec vs 1358.50 +/- 746.53 sec, p= 0.038); no differences were found in terms of skin-to-skin time and fluoroscopy time.

Conclusions

To perform a LAT map during pacing from distal CS may help to better identify residual gaps in redo AF procedures, allowing a reduction in radiofrequency time, without increasing skin to skin time and fluoroscopy time.Discrepancy between bipolar and LAT map
Intermittent hypoxia is significantly associated with low-voltage areas in patients with atrial fibrillation complicated by obstructive sleep apnea
Authors: Takada Y , Yazaki Y , Shiina K , Terasawa M
Published: May 2024

Background

Obstructive sleep apnea (OSA) is one of risk factors for atrial fibrillation (AF); however, how OSA affects the structural and electrical atrial remodeling is not well described. This study aimed to determine the association of OSA with left atrial (LA) size and LA low-voltage area (LVA), a known arrhythmogenic substrate for AF.

Methods

Eighty-three patients undergoing catheter ablation of AF (forty-nine with OSA [apnea–hypopnea index: AHI ≥ 5/h] and thirty-four control patients without OSA by full polysomnography or portable monitor) were studied. In all cases, LA maps were created using a three-dimensional electro-anatomical mapping system in sinus rhythm or pacing from the right atrium. LVA was defined as a bipolar voltage < 0.5 mV. %LVA is defined as ratio of LVA to LA area.

Results

LVA and %LVA were larger in OSA group as compared to Control group (6.0 ± 6.6 vs. 2.6 ± 3.2 cm2, P = 0.003 and 7.5 ± 8.5 vs. 3.5 ± 4.6 %, P = 0.008, respectively). On the other hand, there was no difference in LA size between the two groups. In addition, 3% oxygen desaturation index (ODI) was significantly correlated with %LVA (r = 0.282, P = 0.010), but not with LA size (r = 0.053, P = 0.637). Multiple regression analysis demonstrated that 3%ODI ≥ 30 (3.088, 1.078-8.851, P = 0.036) was significantly associated with %LVA after adjustment.

Conclusion

In patients with AF complicated by OSA, significant enlargement of the LVA was observed, but there was no evidence of enlargement in LA size. Intermittent hypoxia may be one of the mechanisms of this atrial electro-anatomical remodeling.figure 1figure 2
Pulsed-field vs. cryo-balloon based pulmonary vein isolation: does reduced autonomic modulation effect freedom of atrial fibrillation?
Authors: Lemoine M , Jaeckle S , Obergassel J , Mencke C , Riess J , Ismaili D , Wenzel J P , My I , Moser F , Rottner L , Reissmann B , Ouyang F , Kirchhof P , Rillig A , Metzner A
Published: May 2024

Background

Pulsed-field ablation (PFA) is a new energy source integrated into single-shot devices enabling pulmonary vein isolation (PVI) during atrial fibrillation (AF) ablation. It has been demonstrated that PFA is noninferior to conventional thermal ablation. Conceptually, PFA preferentially damages cardiomyocytes and our prior data show that PFA causes less damage to neuronal tissue and reduced autonomic dysfunction than CBA. Here, we analyzed heart rate variability (HRV) as an additional parameter of intracardiac nervous system and whether the damage to neuronal tissue quantified by biomarker release and functional parameters might influence the recurrence rate of atrial fibrillation in PFA and CBA treated patients.

Methods

We prospectively included consecutive patients with paroxysmal AF undergoing index PVI applying PFA (n=65) or CBA (n=112). We quantified the ablation-dependent effect on intracardiac autonomic nervous system by comparing resting heart rate (HR), HRV and circulating concentrations of the neuronal biomarker S100B. Recurrent AF was detected using Holter ECGs, wearables and telephone interviews.

Results

Baseline characteristics did not differ between PFA and CBA (age 66 vs. 68 years, female 33% vs. 39%, CHADS-VASc Score 2.1 vs. 2.2, indexed LA volume 32 vs. 31 ml/m², BMI 27.3 vs. 27.4 kg/m²). After CBA-based PVI, HR increased (pre 63 vs. post 70 bpm, p<0.001) and HRV decreased (SDNN pre 54 vs. post 26 ms, p=0.007). After PFA-based PVI, HR and HRV remained stable (HR pre 63 vs. 64 bpm, p=0.591; HRV SDNN pre 37 vs. post 36 ms, p=0.890). In a direct comparison, the HR-increase and HRV-decrease observed after CBA-based PVI was significant compared to PFA (0.8 vs. 7.3 bpm, p<0.001 and SDNN -1 vs. 29 ms, p=0.003). We reported previously that PFA induced less S100B release (28 ng/dl) than CBA (68 ng/dl, p<0.001) and that PV reconnection rates in ReDo procedure were similar between PFA (40%) and CBA (40%). 1 year follow-up revealed freedom of AF in 79% after PFA and 73% after CBA (p=0.230). Dividing patients in upper and lower half of HR increase and S100B release after PVI, patients showed no difference in recurrence rates after CBA.

Conclusion

These data suggest that neurocardiac damage near the pulmonary veins seems not to contribute to freedom of AF recurrences after PVI.
Impact of obesity and pattern of atrial fibrillation on long-term outcome following cryoballoon pulmonary vein isolation
Authors: Musat D , Milstein N S , Park L S , Bhatt A , Habibi M , Kochav S , Preminger M , Sichrovsky T , Shaw R , Mittal S
Published: May 2024

Background

Cryoballoon (CB) pulmonary vein isolation (PVI) is an accepted method for treatment of paroxysmal and persistent atrial fibrillation (PAF, PeAF). Obese and PeAF patients do worse following ablation. However, there are limited data on the impact of both variables on outcomes.

Objective

To understand the impact of obesity and AF pattern on long-term outcomes following CB PVI.

Methods

We enrolled consecutive AF patients undergoing CB PVI; all patients had an implantable loop recorder (ILR) for long term continuous monitoring. Obesity (O) was defined as a BMI ≥ 30 kg/m2. The cohort was divided into 4 groups based on presence of obesity and type of AF at the initial ablation: (1) N-O (non-obese) and PAF, (2) O and PAF, (3) N-O and PeAF, and (4) O and PeAF. We assessed long-term AF recurrences, after excluding an initial 3-month post-ablation blanking period.

Results

The cohort included 322 patients (67 ± 9 years; 209 [65%] male; 177 [55%] PAF; CHA2DS2-VASc 2.7 ± 1.6, 137 [43%] O). Obese patients were younger and more likely to have hypertension and diabetes. During a follow-up of 931 ± 599 days, 211 (66%) patients had recurrent AF. The best outcome was seen in N-O obese patients with PAF; all other groups fared similarly (Figure). Group 1 had significantly lower AF recurrence compared to all 3 other groups (Figure). In multivariate analysis, obesity/AF type was the only significant predictor of AF recurrence (Table). As compared to N-O PAF pts, O PeAF patients had a 2-fold greater likelihood of AF recurrence.

Conclusions

During almost 3-years of objective follow-up, we found that CB PVI performs best in non-obese pts with PAF. Once obesity occurs, PAF pts respond as poorly to PVI as pts with PeAF, irrespective of obesity status. Additional strategies are needed in these patients.
Multielectrode catheter-based pulsed electric field versus cryoballoon for atrial fibrillation ablation: a systematic review and meta-analysis
Authors: Vetta G , Della Rocca D G , Parlavecchio A , Magnocavallo M , Pannone L , Sorgente A , Sieira J , Almorad A , Bala G , Stroker E , Rossi P , Boveda S , Sarkozy A , De Asmundis C , Chierchia G B
Published: May 2024

Background

Pulsed field ablation (PFA) is an innovative technology recently adopted for the treatment of atrial fibrillation (AF). Preclinical and clinical studies have reported a remarkable safety profile, as a result of its tissue specific effect targeting cardiomyocytes and sparing adjacent tissues. The FarapulseTM system was the first PFA device to receive regulatory approval.

Objective

We performed a meta-analysis to compare the efficacy and safety of PFA with the FarapulseTM system versus currently available 2nd generation Cryoballoon technologies (CRYO).

Methods

We systematically searched electronic databases for studies focusing on AF ablation employing the FarapulseTM PFA or 2nd generation CRYO technologies. The primary endpoints were acute procedural success assessed on a vein and patient basis. Safety endpoints included overall periprocedural complications and major periprocedural complications. We also compared procedural, fluoroscopy times, and freedom from atrial tachyarrhythmias (ATs) at follow-up (secondary endpoints).

Results

Fifteen and 69 studies were included for PFA and CRYO, respectively. PFA demonstrated greater acute procedural success on a vein basis (99.9% vs 99%;p<0.001), as well as per patient (99.5% vs 98.4%;p<0.001). PFA yielded lower overall periprocedural complications (3.0% vs 5.7%;p<0.001) and shorter fluoroscopy time (14.0 min vs 18.9 min;p=0.02) compared to CRYO (Figure 1). No differences were found for major periprocedural complications (1.2% vs 1.0%;p=0.37), procedural time (84.4 min vs 106.2 min;p=0.07) (Figure1) and freedom from ATs at 1 year (81.8% vs 80.3%; Log-rank p =0.98) (Figure 2).

Conclusions

PFA contributed to higher acute procedural success, and safety compared to CRYO. No statistically significant differences in AT recurrence at 1-year follow-up were observed.Figure 1Figure 2
Pattern of reconnection after isolation of the pulmonary veins with a pulsed-field ablation
Authors: Finet F , Jean F , Massoulie G , Boudias A , Catalan P A , Clerfond G , Bouchant-Pioche M , Riocreux C , Eschalier R
Published: May 2024

Background

Pulsed Field Ablation (PFA) has proven is efficacy for pulmonary vein isolation (PVI) with an acute success in 99.9% of PVI and few major complications (1.6% of patients). (1) However, in redo procedures, the durability of the PVI was 63% at a median of 6 month in a study of Kueffer and al. (2)

Purpose

The purpose of this study is to analyze the pattern of these reconnections in the redo procedures.

Methods

We retrospectively analyzed the data among the patients that had a PVI with PFA in our institution between 1 October 2022 and 1 October 2023 who were referred for a recurrence of a tachyarrhythmia.

Results

Of 350 patients treated for PVI with PFA, 14 patients (4%) were referred for a recurrence of tachyarrhythmia. Among them, three (21%) were female and the median age was 72 years old [IQR 69-78]. The Chadvasc score was > 2 in 7 (50%) patients and the DR flash score was > 3 also in 7 (50%) patients. The patients were referred for paroxysmal AF (4/14 patients), persistent AF (5/14 patients), typical flutter (2/14 patients) or atypical flutter (3/14 patients). All patients had a high resolution 3D electro-anatomical mapping, in a median time of 7,4 months [IQR 5,1-11,8]. The median left atrium volume was 169 mL [IQR 150-180] and 66% of the pulmonary veins were isolated. Only two patients (14%) had durable PVI in all their veins. Two of the patients had a posterior box with their PVI and the box was blocked at 7 and 13 months after the PFA. The reconnections of the pulmonary veins was mainly in the anterior aspect of the right superior PV (6/19 reconnections, 32%). There were two typical shapes of reconnection, the « missing petal » and the « collar » patterns.

Conclusion

In a redo procedures at 7 months after a PFA, 14% of the patients had durable PVI and 66% of the veins were isolated. The reconnections were mainly in the anterior right superior PV and had often a typical « missing petal » or « collar» patterns.Percentage ReconnectionsPatterns Reconnections
Hybrid ablation versus repeated catheter ablation in persistent atrial fibrillation: long-term results of the HARTCAP-AF trial
Authors: Van Der Heijden C A J , Vroomen M , Weberndorfer C V , Luermans J G L M , Chaldoupi S M , Bidar E , Vernooy K , Maessen J G , Van Kuijk S M J , La Meir M , Crijns H J G M , Maesen B A E
Published: May 2024

Background

The HARTCAP-AF study compared the efficacy and safety outcomes in forty-one ablation-naive patients with persistent atrial fibrillation (AF) randomized to thoracoscopic hybrid ablation (HA) or stand-alone catheter ablation (CA). One-year results have shown that thoracoscopic HA has superior rhythm outcomes than CA, without increasing complications.

Purpose

Here, we evaluated the efficacy, safety and quality of life (QOL) of thoracoscopic HA and CA within a long-term follow-up (FU) duration of three years.

Methods

Efficacy outcomes included freedom from atrial tachyarrhythmia (ATA) recurrences ≥5 minutes off and allowing antiarrhythmic drugs (AAD) after 24 and 36 months. Safety outcomes, including serious adverse events (SAEs), and QOL, measured by the EHRA AF symptom score, were evaluated after 36 months.

Results

After a mean FU duration of 25±3 and 38±3 months, freedom from ATA recurrences was higher in the HA group compared to the CA group off AAD (68.4% vs. 22.7%, P=0.002 and 57.0% vs. 22.7%, P=0.005) and allowing AAD (73.7% vs. 22.7%, P=0.001 and 63.2% vs. 22.7%, P=0.001) (Figure 1, Table 1). The number of redo catheter procedures was higher in the CA arm than the HA arm (n=15 vs. n=3, P=0.021). The total number of SAEs was low and did not differ between groups (HA: n=6 vs. CA: n=7, P=0.989). Moreover, QOL measured by the EHRA AF-symptom score improved for both groups post-procedure (3.2±0.7 and 1.6±0.78, P<0.001) and were better for HA than CA after 3 years (1.3±0.7 and 1.9±0.8, P=0.029).

Conclusion

After three years, (thoracoscopic) HA continues to have superior rhythm outcomes compared to CA with a comparable long-term safety profile. While both procedures resulted in a reduction in AF symptoms, EHRA scores were more favorably scored by patients in the HA arm. Therefore, in experienced centers thoracoscopic HA should be considered as a first-line treatment to percutaneous approaches for ablation-naive patients with persistent AF.Figure 1Table 1
Aspirin versus clopidogrel as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation
Authors: Kim T S , Kim S , Park S , Kim H , Hwang Y , Kim S H , Kim J H , Jang S W , Oh Y S , Choi Y
Published: May 2024

Background

Patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) are recommended to receive dual antithrombotic therapy including an antiplatelet agent and direct anticoagulants (DOAC). We compared the effectiveness between aspirin and clopidodgrel for a combination therapy with DOAC in this population.

Methods

We analyzed patient data from the Korea National Health Insurance Service. A total of 9,157 patients with AF who received dual antithrombotic therapy after PCI were included. Patients were classified into the aspirin group and clopidogrel group, and 1:1 propensity score matching (PSM) was performed. The primary ischemic endpoint was a composite of cardiovascular death, myocardial infarction, stroke, or systemic thromboembolism. A major bleeding event was defined as a bleeding event requiring hospitalization.

Results

After PSM, there were each 2,882 patients each in the aspirin and clopidogrel group. The incidence of the primary ischemic endpoint was similar in the two groups (22.8% vs. 21.8%, in the aspirin and clopidogrel group, hazard ratio [HR] for clopidogrel group: 0.909, 95% confidence interval [CI] 0.815 – 1.014). The incidence of each component of ischemic endpoint did not differ significantly between the two groups. All-cause mortality was increased in the clopidogrel group (HR 1.301, 95% CI 1.000 – 1.692). There was no significant difference in major bleeding events (HR 0.942, 95% CI 0.789 – 1.126).

Conclusions

For a dual antithrombotic therapy in patients with AF who had undergone PCI, aspirin and clopidogrel did not differ in terms of ischemic outcomes, but the use of aspirin was associated with slightly lower all-cause mortality.
Patient-reported treatment burden: comparison between vitamin-K antagonist and non-vitamin K antagonist oral anticoagulants
Authors: Mihajlovic M , Nevena Z , Simic J , Marinkovic M , Mujovic N , Potpara T
Published: May 2024

Introduction

Treatment burden (TB) is defined as the overall workload that maintenance or improvement of their functioning and well-being poses on patients with chronic medical conditions. A high patient-reported TB has been associated with lower adherence to treatment and increased risk of major adverse events including death. We explored the differences in patient-reported TB value and prevalence of unacceptably high TB score (≥59 points) between patients receiving vitamin K antagonist oral anticoagulants (VKA) and non-vitamin K antagonist oral anticoagulants (NOAC). Furthermore, we explored contributory factors associated with TB and the relationship between TB and quality of life (QoL) in these patients.

Methods

A single-centre study included consecutive adult in- and outpatients on long-term oral anticoagulation, seen at a university clinical centre a from April to June 2019, who were willing to complete the Treatment Burden Questionnaire encompassing 13 items assessing the TB associated with taking medicine, self-monitoring, laboratory assessments, medical consultations, organisational and administrative requirements, adherence to dietary and physical activity recommendations, as well as the social repercussions of the treatment.

Results

Of 320 enroled patients, 206 (64.4%) were taking a VKA. Atrial fibrillation was the most common indication for long-term oral anticoagulation (n=299, 93.4%). The mean TB score was significantly higher in patients on VKA versus those taking a NOAC (48.8 ±26.5 vs. 41.8 ±19.7, P= 0.014), mostly owing to significantly higher TB values for questions related to self-monitoring, including the International Normalized Ratio (INR) control (3.85±3.32 vs. 1.62±1.38, P<0.001) and diet restrictions (3.98±3.43 vs. 2.48±2.49, P<0.001) in patients taking VKA (Figure 1). In addition, these patients significantly more often reported an unacceptably high TB of ≥59 points compared with those taking NOAC (30.1% vs 18.4%, P= 0.024). Multivariable regression analysis of predictors of TB in patients taking a VKA or NOAC are presented in Table 1.

Conclusion

In our study, patients receiving a VKA reported significantly higher TB compared to those using NOAC, especially regarding the questions about self-monitoring (including INR control) and diet restrictions. An unacceptably high TB was also more prevalent among patients receiving a VKA. Our findings suggest that prescribing NOACs in preference to VKAs could help in decreasing the self-reported TB in patients who need oral anticoagulant therapy.
Percutaneous left atrial appendage closure using a novel occlusion device for thromboembolic prevention: 3-year procedural experience
Authors: Moser F , Rottner L , My I , Lemoine M , Ismaili D , Kirchhof P , Reissmann B , Ouyang F , Rillig A , Metzner A
Published: May 2024

Background

Stroke due to atrial fibrillation has been associated with a high risk of disability and mortality. Percutaneous left atrial appendage (LAA) closure has been established as a treatment strategy for stroke prevention in patients not eligible for oral anticoagulation as well as in patients after electrical isolation of the LAA and subsequent increased risk of thrombus formation. The aim of this study was to evaluate the feasibility and initial experience of LAA closure using a novel nitinol-based, self-expanding system in an unselected patient cohort.

Methods and Results

One hundred and two patients (39% female, median age 75 [71;80], median CHA2DS2-VASc score 5 [4;6]) underwent LAA closure with the novel system between October 2020 and October 2023. 61/102 (61%) patients underwent previous electrical LAA isolation, 30/102 (29%) patients had high bleeding risk as an indication for LAA closure. Median procedure time was 45 [38;59] minutes and median fluoroscopy time was 10 [7;12] minutes. Successful LAA closure was achieved in all patients, despite different LAA anatomies. Median umbrella and cover disc diameter were 22 [20;24] millimeter and 28 [20;24] millimeter, respectively. Procedure-related adverse events occurred in 2/111 (1.8%) patients. One patient had a vascular complication at the puncture site and another patient had non-hemodynamically significant pericardial effusion. Overall, the patients stayed for a median of 2 [1;4] days in hospital.

Conclusion

Left atrial appendage closure with a novel nitinol-based, self-expanding system is feasible and safe. LAA isolation was the most common indication for LAA closure at our institution. Further studies are needed, to identify differences and potential advantages of different LAA closure systems.
Increased left atrial pressure is associated with fibrosis, elevated mechanical load and ventricular diastolic dysfunction in patients undergoing AF catheter ablation
Authors: Tanacli R , Bock M , Bartels F , Hindricks G , Gerds-Li J H , Hohendanner F
Published: May 2024

Background

Increased left atrial filling pressures might be a hallmark feature of atrial cardiomyopathy which has been associated with an increased incidence of atrial fibrillation (AF) recurrence even after successful pulmonary vein isolation (PVI). The interplay between left atrial pressure, measured during the ablation procedure, and other parameters characterising atrial and ventricular remodelling in patients with AF remains elusive.

Methods and Results

Between 2018 and 2022, 182 patients undergoing PVI for paroxysmal or persistent AF were included in the study. Mean left atrial pressure (mLAP) was measured invasively during the ablation procedure after transseptal puncture. A mLAP higher than 15 mmHg was considered the cut-off value for LA hypertension. Bipolar high-density 3D electro-anatomical maps (Carto) obtained during the procedure were used to manually quantify low-voltage (<0.5 mV) and normal voltage areas of the LA surface and a global low-voltage/normal voltage ratio index was derived. Contemporary transthoracic echocardiography data were included to evaluate LV systolic and diastolic function and blood samples were obtained post-procedurally from all patients. In bivariate linear regression analysis, mLAP reached only modest correlation with E/e’ as an imaging marker of diastolic dysfunction (R=0.31, p=0.005) (Figure 1A), with particular differences in mLAP values between patients with marked diastolic impairment (E/e’ > 15) vs. subgroups with mild dysfunction ( 8 < E/e’ ≤ 15) or normal diastolic function (E/e’ ≤ 8 ) (Figure 1B), log NT proBNP (R=0.34, p<0.001) (Figure 1C) and low-voltage/normal voltage ratio index (R=0.21, p=0.014) (Figure 1D). For a total of 158 patients, data about 1 year recurrence of AF were available, of these 22 (13.9%) had a recurrence after two procedures using cryo-energy for the index PVI and radiofrequency ablation for the re-PVI (second procedure). A Kaplan-Meier analysis and log-rank test showed a trend but no statistical significance regarding an increased AF recurrence rate between patients with and without LA hypertension (χ2 = 2.63, p= 0.09) (Figure 2).

Conclusion

Direct intra-procedural invasive measurement of LA pressures can offer an important and convenient novel piece of information for patients undergoing catheter ablation procedures for AF, with potential implication for post-procedural recurrence risk stratification. Atrial hypertension is only partially related to LV diastolic impairment, atrial fibrosis and myocardial mechanical load burden.
A novel method to identify critical isthmus of right atrial reentrant tachycardia; Functional substrate mapping characteristics during sinus rhythm
Authors: Yorgun H , Coteli C , Kilic S , Aytemir K
Published: May 2024

Background

Right atrial tachycardia (AT) is a frequent rhythm disorder in patients with atrial scar mainly due to surgical incisions or congenital heart diseases. Despite the mounting evidence about AT mechanisms and types, data is scarce regarding the conduction properties as well as functional characteristics of atrial substrate during sinus rhythm that has role in the maintenance of the tachycardia.

Purpose

We sought to evaluate the relationship between the functional substrate mapping (FSM) characteristics of right atrium and the critical isthmus (CI) of re-entrant ATs in patients with underlying atrial scar.

Methods

Among patients with the history of right AT who underwent catheter ablation with 3-D mapping were retrospectively enrolled. Voltage map and isochronal late activation mapping (ILAM) were created during sinus / paced rhythm using multielectrode catheters to detect deceleration zones (DZ). Subsequently AT was induced with programmed stimulation and activation mapping was performed to detect CI of the tachycardia. Atrial tachyarrhythmia (ATa) recurrence was defined as detection of atrial fibrillation or AT (≥ 30 s) during the follow-up.

Results

A total of 24 patients [mean age: 46 ±15, gender: 13 (54 %) female] with right AT were included. A total of 37 ATs were mapped [16 (43.2%); localized reentry, 21 (56.7%), macroreentry]. Atrial low voltage zones comprised 23.3 ± 13.0 % of total right atrium. The mean value of bipolar voltage, EGM duration and conduction velocity during sinus rhythm corresponding to CI of ATs were 0.18 ± 0.10 mV, 121.7 ± 29.4 ms, 0.06 ± 0.04 m/s and, respectively. Total number of DZs per chamber was 1.1 ± 0.3, which were all located in the low-voltage zone (<0.5 mV) detected by high density mapping. All CIs of non- cavo-tricuspid-isthmus (CTI) dependent reentry were colocalized with DZs detected during FSM. The positive predictive value of DZs to detect CI of inducible ATs is 80.8%. During the mean follow-up of 11.7 ± 8.1 months, freedom from ATa was 87.5%.

Conclusion

Although, CTI-dependent macroreentry is the most common mechanism in patients with RA scar, our findings demonstrated the relevance of FSM to predict non-CTI dependent ATs. Conduction slowing manifested as DZs with continuous-fragmented signal morphology may guide to tailor ablation strategy in case of underlying RA scar.
Premature ventricular contractions increase with heart rate in patients with mitral valve prolapse
Authors: Bugge C , Five C K , Castrini A I , Ribe M , Haugaa K H , Aabel E W
Published: May 2024

Background

A subset of patients with mitral valve prolapse (MVP) are at risk of life-threatening ventricular arrhythmias (VAs), and a high burden of premature ventricular contractions (PVCs) is associated with increased mortality in patients with MVP. Previous studies indicate that PVC burden could either increase with increasing heart rate (HR), decrease with increasing HR, or with no relationship to HR. The association between PVC burden and HR in MVP is not known, nor if there is an association with VAs.

Purpose

We aimed to explore the relationship between PVC burden and HR in patients with MVP. Furthermore, we aimed to explore whether the different PVC profiles were associated with severe VA.

Methods

In this cross-sectional ambispective outcome study, we included patients with MVP and available Holter monitorings with >100 PVCs per 24-hours seen at our tertiary centre. The Holter monitoring with the highest PVC burden was used in case of multiple recordings. We investigated the relationship between hourly PVC burden and hourly mean HR by univariable mixed linear regression. We defined PVC profiles as (1) fast-HR-dependent-PVC (F-HR-PVC) when there was a significant positive correlation, (2) slow-HR-dependent-PVC (S-HR-PVC) when there was a significant negative correlation, and (3) independent-HR-PVC (I-HR-PVC) when no correlation between PVC and HR was found. The significance was set to 0.05. Severe VA was defined as sustained ventricular tachycardia, non-sustained ventricular tachycardia with haemodynamic instability, ventricular fibrillation, aborted cardiac arrest, or appropriate shock by a primary preventive implantable cardioverterefibrillator. Severe VA was recorded from retrospective medical history, prospective ICD interrogation or monitoring with implantable loop recorder.

Results

We included 75 patients with >100 PVCs at Holter monitoring (median age 48 years [IQR 35-58], 58% female). The median PVC burden was 1.9% per 24-hours (IQR 0.4-7.2). We found F-HR-PVC in 49 patients (65%), S-HR-PVC in 1 (1%), and I-HR-PVC in 25 (33%). Twelve (16%) patients had severe VA and these had higher PVC burden compared to those without severe VA (7.3% per 24-hours [IQR 4.2-10.4] vs 1.1% per 24-hours [IQR 0.3-5.3], p=0.004). The median PVC burden was 1.5% (IQR 0.3-8.0) for F-HR-PVC, 5.7% for S-HR-PVC and 1.5% (IQR 0.3-8.0) for I-HR-PVC. We found no association between different PVC profiles and the presence of severe VA (F-HR-PVC 65% vs 67%, S-HR-PVC 2% vs 0%, I-HR-PVC 33% vs 33%, p>0.05 for all groups).

Conclusion

Fast-HR-dependent-PVC was most common in MVP patients, and slow-HR-dependent-PVC were rare. A higher PVC burden was associated with severe VA. However, different PVC profiles did not infer higher risk of severe VA in our study. Further studies are needed to explore whether distinct PVC profiles can predict severe VA in larger patient populations.
Initial experience with ablation of ventricular arrhythmias using a pulsed-field system
Authors: Peichl P , Wichterle D , Stojadinovic P , Borisincova E , Stiavnicky P , Haskova J , Cihak R , Kautzner J
Published: May 2024

Introduction

Catheter ablation using radiofrequency (RF) current is a well-established method of treatment of ventricular arrhythmias (VA). However, RF ablation may fail to eliminate deeply located arrhythmogenic substrate. Pulsed-field (PF) is a novel energy source with a potential to create deeper lesions, especially in scar tissue.

Purpose

This study aims to present the data on safety and efficacy (acute outcome data) of VA ablation using PF.

Methods

The population consists of 15patients (5 women, age: 61 ± 19years) after previously failed RF ablation of VA. The underlying condition was nonischemic cardiomyopathy (53%), coronary artery disease (13%), and congenital heart disease (13%), respectively. No structural heart disease was present in 20% of cases. The mean left ventricular ejection fraction was 39 ± 13%. Eighty percent of patients had sustained VA, the remaining patients presented with frequent ventricular ectopy. Ablation was performed using a conventional irrigated 4-mm tip catheter in a combination with commercially available PF generator. Peripheral venous blood samples for the assessment of the plasmatic levels of high-sensitivity troponin T (hsTnT) were obtained the next day (usually 18-24hours) after the procedure.

Results

A mean of 17±12 PF applications (25A) per patient were delivered. In 5 patients (33%), an additional RF ablation (4±9 applications) was performed. Acute success as assessed by non-inducibility of VA or elimination of ectopic focus was achieved in all but one patient (93%). In 4 cases (27%), PF energy was applied within the great cardiac vein and subsequent coronary angiography did not reveal any abnormality. On the other hand, transient conduction system block occurred in 3 cases (20%) during PF application on the lateral LV wall remotely from the LV septum (complete AV block in one, LBBB in two patients). These events resolved in all cases within one hour. Ablation using PF did not result in excessive increase of hsTnT (657±482ng/l, with upper reference level of 14ng/l).

Conclusion

Initial experience with PF for the treatment of VA indicates high acute efficacy. The long-term effect is to be determined. PF applications in the ventricle may be associated with unexpected but transient conduction system damage, even when applications are performed remotely from the interventricular septum. The postprocedural increase in plasma troponin levels is only moderate.
An optimized multisource acquisition and registration workflow for imaging guided ventricular tachycardia ablation
Authors: Parollo M , Torre M , Fiorentini F , Di Cori A , Segreti L , Grifoni G , Notarstefano P , De Sensi F , Rossi A , Lapira F , Cardelli L , Santoro A , Aquaro G D , Faggioni L , Zucchelli G
Published: May 2024

Background

Catheter ablation is a cornerstone treatment for scar-related ventricular arrhythmias arising in patients affected by structural heart disease. Imaging integration with electroanatomical mapping (EAM) suites for ventricular tachycardia (VT) ablation procedural guidance is an established step for advanced substrate characterization and treatment.

Purpose

To compare and validate different approaches for intraprocedural multisource imaging registration and integration with EAM suites for VT ablation guidance.

Methods

Thirty consecutive patients prospectively enrolled in the ongoing VOYAGE clinical trial for imaging guided/aided VT ablation at our center were retrospectively analyzed. Multidetector computed tomography (MDCT) and late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) imaging was performed before procedure. MDCT and LGE-CMR images were both acquired during end-expiratory breath hold. Same cardiac cycle phase images were used. Wide band LGE-CMR was acquired in case of a cardiac implantable electronic device was present to reduce artifacts. Images were imported in ADAS3D software. MDCT and CMR images were manually registered using established anatomical landmarks (left ventricle outflow tract, left ventricle apex, papillary muscles, left and right ventricle junction), were then respectively processed for aortic/ventricular anatomical reconstruction and myocardial characterization and then imported in CARTO3 electroanatomical mapping suite for procedural guidance.

Registration between EAM and imaging was either performed with ascending aorta fast anatomical mapping (FAM) and 3D landmark alignment with aortic MDCT or via intracardiac echocardiography (ICE) left ventricle (LV) chamber segmentation and 3D landmark alignment with ventricular MDCT. ICE segmentation was also obtained for every case regardless of aortic FAM. Surface match between ICE and MDCT LV chamber reconstructions was calculated for method comparison.

Results

All 30 patients had an ICE segmentation of the LV, with a mean of 15,66±4,89 contours. Aortic FAM was obtained and used for aortic MDCT registration in 10 subjects. LV ICE was instead used for imaging alignment in 20 subjects. When compared to aortic FAM, LV ICE to LV MDCT alignment achieved lower average surface distance (3,86±1,41 mm vs 8,884±6,77 mm; p<0,001), lower minimum surface distance (0,002±0,03 vs 0,07±0,06; p= 0,001) and lower maximum surface distance (14,16±4,37 vs 22,93±11,10; p<0,001).

Conclusion

An optimized workflow consisting of ICE LV chamber segmentation was superior in terms of 3D surface distance to aortic FAM reconstruction to obtain reliable multisource imaging registration for MDCT/CMR guided/aided VT ablation.
Device programming and SMART pass algorithm activation in subcutaneous implantable defibrillator patients: data from a remote monitoring database
Authors: Iacopino S , Santobuono E , Cocchiara L , Giammaria M , Lavalle C , Pecora D , Mahfouz K , Bertini M , Filannino P , Artale P , Valsecchi S , Bianchi V
Published: May 2024

Background

In subcutaneous implantable cardioverter-defibrillator (S-ICD) recipients, a previous study demonstrated very low rates of delivered shocks and inappropriate shocks on programming a conditional zone between 200 and 250 bpm and a shock zone for arrhythmias >250 bpm. The extent to which this programming approach is adopted in clinical practice has been little studied, as the activation status of the SMART Pass filter, that was implemented to reduce inappropriate shocks and enhanced over time.

Purpose

We assessed device programming during follow-up and the rate of detected arrhythmias in a cohort of consecutive S-ICD recipients.

Methods

We analyzed data from 670 S-ICD patients followed on the remote network at 17 Italian centers for a median of 31 months (25th-75th percentile: 16-51). The enhanced SMART Pass version was available for all patients after October 2022. It makes the deactivation monitor less sensitive to premature ventricular contractions or other transient amplitude changes while maintaining arrhythmia sensitivity and specificity, and it was expected to reduce unintentional deactivation rate.

Results

At the last remote data transmission, the median programmed conditional zone cut-off was set to 210 bpm (25th-75th percentile: 200-220), the shock zone cut-off was 250 bpm (25th-75th percentile: 240-250), and the SMART Pass was enabled in 586 (87%) patients. During follow-up, 194 automatic deactivation events (0.10/patient-year) were reported in 118 (18%) patients. The SMART Pass-disabled time was 13% of the total observation period. Shocks were delivered in 129 (19%) patients (rate: 0.13/patient-year), and untreated arrhythmias were recorded in 136 (20%) patients (rate: 0.14/patient-year). The rate of shocks was lower when SMART Pass was enabled – 0.12/patient-year (95% CI: 0.10-0.14) versus 0.20 (95%CI: 0.15-0.26) (p=0.002), as it was the rate of untreated arrhythmias – 0.12/patient-year (95% CI: 0.11-0.14) versus 0.23 (95%CI: 0.18-0.30) (p=0.001). The enhanced SMART Pass version was associated with a lower rate of deactivations – 0.04/patient-year (95%CI: 0.02-0.05) versus 0.14 (95% CI: 0.12-0.16) (p<0.001), and with a reduction in treated and untreated arrhythmias (Incidence rate ratios: 0.40 (95%CI: 0.28-0.53) and 0.40 (95%CI: 0.30-0.55), respectively (p<0.001)).

Conclusions

In current clinical practice, S-ICD implantation centers often program high cut-off rates for arrhythmia detection. Most patients have SMART Pass consistently enabled during follow-up. This is associated with significantly lower rates of detected and treated arrhythmias. The enhanced SMART Pass version seems associated with lower deactivation rate, and with further decrease in treated and untreated detected arrhythmias.
Mid-term outcomes after stereotactic arrhythmia radioablation for refractory ventricular tachycardia
Authors: Teres C , Luca A , Le Bloa M , Solana J , Ascione C , Domenichini G , Pascale P , Bourhis J , Verhoeff J J , Blanck O , Pruvot E
Published: May 2024

Introduction

stereotactic arrhythmia radioablation (STAR) is used as a rescue treatment for refractory ventricular tachycardia (VT) originating from unreachable myocardial substrate following unsuccessful radiofrequency catheter ablation (RFCA). The mid-term outcomes of STAR, however, remain poorly known.

Objective

to report the mid-term efficacy and safety outcomes in our series of 21 patients (pts) treated by STAR over 6 years.

Methods

Inclusion of consecutive pts treated by STAR with a Cyberknife system between 2017 and 2023. 3D-electroanatomical maps (EAM) of the VT substrate during unsuccessful RFCA were used to delineate the planned target volumes (PTV) on a 4D CT scan. Patients were followed up at least every 6 months by echocardiography and ICD interrogation at the outpatient clinic.

Results

21 pts [16 (76 %) male, age 66±8 years] with a mean LVEF of 40±15% were included. The underlying substrate was ischemic in 7 (33 %); non-ischemic dilated in 7 (33 %); inflammatory in 4 (19%); hypertrophic in 1 (5%); neoplasic in 1 (5%); and malignant mitral valve prolapse in 1 (5%). A dose of 21±2 Gray was delivered to the PTV (26 ml, IQR 18-43 ml). After a median follow-up of 39 [IQR, 14-48] months, 12 pts (57%) remained in stable condition, 1 (5%) underwent a heart transplantation, 1 (5%) a left ventricular assistance device, 1 (5%) was in an incessant slow VT and 6 (29%) pts died (3 from end stage heart failure). 15 (71%) pts presented VT recurrences [7 (33%) ATPs; 3 (14%) shocks; 4 (19%) VT storm and 1 (5%) with a well-tolerated slow VT (100 bpm) with an LVAD till transplantation, of whom 9 (43%) required redo RFCA. The median value of total ventricular arrhythmic burden (defined as any arrhythmia requiring ICD therapies) decreased significantly from 31 (IQR, 4-100) to 7 (IQR, 1-23) (p<0.05); for nsVT from 57 (IQR, 1.5- 1196) to 41 (IQR, 0.5-584) (p ns); or ICD shocks from 1.5 (IQR, 0-5.5) to 0 (IQR, 0-2) (p<0.05); for ATPs from 21 (IQR, 2.5-94) to 4 (IQR, 0.5-13) (p<0.05). Figure 1 shows a graphic representation of arrhythmic burden before and after STAR.

Conclusion

in this cohort of highly selected pts with refractory VT, STAR significantly reduced the arrhythmic burden by a factor of 4 over a 3-year follow-up. Death rate remained high (29%), mostly by terminal heart failure. Nevertheless, a high proportion of pts had VT recurrences that were successfully managed by redo RFCA.VT burden before and after STAR
Skeletal muscle index as a prognostic marker for sudden cardiac death in heart failure patients with reduced ejection fraction
Authors: Li X , Gao Y U A N , Chen K E P I N G , Niu H X , Zhang S H U
Published: May 2024

Background

The association between sarcopenia and sudden cardiac death remains unclear. Therefore, this study aimed to explore the association between sarcopenia, sudden cardiac death, and all-cause mortality in heart failure (HF) patients with reduced ejection fraction based on the skeletal muscle index (SMI) predicted by a formula.

Methods

A total of 300 patients with heart failure who were admitted to our Hospital, National Center for Cardiovascular Diseases, between March 2013 and November 2015 and met the inclusion criteria were retrospectively analyzed. Baseline SMI was divided into two groups: lower than or equal to the median (n=151) and higher than the median (n=149). The primary endpoints were a composite outcome of sudden cardiac death (SCD) or an equivalent event (sustained ventricular events, or appropriate implantable cardioverter-defibrillator (ICD) therapy).The secondary end point was all-cause mortality.

Results

The average follow-up period was 24.40 ± 14.07 months. Atotal of 42 patients (42/300,14.0%) experienced sudden cardiac death or an equivalent event, and 97 patients (97/300, 32.2%) experienced all-cause mortality. Analysis of the Kaplan–Meier survival curves showed that patients with an SMI lower than or equal to the median had a higher risk of sudden cardiac death (P=0.0015) and all-cause mortality (P<0.0001). Multivariate Cox analysis showed that an SMI lower than the median was an independent risk factor for sudden cardiac death (hazard ratio (HR): 2.837, 95% confidence interval (CI): 1.009–7.980, P=0.048) and all-cause mortality (HR: 2.597, 95% CI: 1.384–4.871, P=0.003).

Conclusions

Decreased SMI significantly increased the risk of sudden cardiac death and all-cause mortality in patients with HF and reduced ejection fraction. In a HF population with reduced ejection fraction, attention should be paid to the effect of sarcopenia on prognosis, and active intervention is expected to improve the prognosis of patients.